GOLDMAN SACHS GROUP INC - TSCAN THERAPEUTICS INC ownership

TSCAN THERAPEUTICS INC's ticker is and the CUSIP is 89854M101. A total of 30 filers reported holding TSCAN THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of TSCAN THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$206,318
-90.0%
35,268
-86.4%
0.00%
Q1 2024$2,065,575
+1069.9%
260,148
+759.0%
0.00%
Q4 2023$176,562
+83.9%
30,285
+162.6%
0.00%
Q3 2021$96,00011,5310.00%
Other shareholders
TSCAN THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
DC Funds, LP 630,000$3,685,50061.20%
Lynx1 Capital Management LP 5,224,600$30,563,91011.03%
Propel Bio Management, LLC 2,087,139$12,209,7637.92%
Deer Management Co. LLC 1,245,504$7,286,1981.50%
STEMPOINT CAPITAL LP 845,069$4,943,6541.45%
GREAT POINT PARTNERS LLC 940,831$5,503,8611.05%
EcoR1 Capital, LLC 5,000,000$29,250,0000.90%
BVF INC/IL 2,989,474$17,488,4230.49%
Simplify Asset Management Inc. 1,046,916$6,124,4590.41%
Alphabet Inc. 1,077,080$6,300,9180.32%
View complete list of TSCAN THERAPEUTICS INC shareholders